ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK)
1541.HK Stock Price Chart
Explore ImmuneOnco Biopharmaceuticals (Shanghai) Inc. interactive price chart. Choose custom timeframes to analyze 1541.HK price movements and trends.
1541.HK Company Profile
Discover essential business fundamentals and corporate details for ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541.HK) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
5 Sept 2023
Employees
156.00
Website
https://www.immuneonco.comCEO
Wenzhi Tian
Description
ImmuneOnco Biopharmaceuticals (Shanghai) Inc., a biotechnology company, focuses on the development of immuno-oncology therapies. Its lead product candidate is IMM01, a clinical-stage CD47-targeted molecule for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML) classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). It also develops IMM0306, a CD47×CD20 bispecific molecule for the treatment of R/R B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, a CD47×HER2 bispecific molecule for the treatment of HER2-positive and HER2-low expressing solid tumors; IMM2520, a CD47×PD-L1 bispecific molecule for the treatment of solid tumors; IMM47, a humanized monoclonal antibody targeting CD24 for cancer treatment; MM4701, a bispecific molecule that simultaneously targets CD47 and CD24; IMM2510, a bispecific molecule with a mAb-Trap structure targeting VEGF and PD-L1; IMM27M, a CTLA-4 antibody with enhanced ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody with enhanced ADCC activity. The company was founded in 2015 and is headquartered in Shanghai, China.
1541.HK Financial Timeline
Browse a chronological timeline of ImmuneOnco Biopharmaceuticals (Shanghai) Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 25 Mar 2026
Earnings released on 26 Aug 2025
EPS came in at -$0.41 , while revenue for the quarter reached $41.68M .
Earnings released on 25 Mar 2025
EPS came in at -$0.22 , while revenue for the quarter reached $43.61M .
Earnings released on 31 Dec 2024
EPS came in at -$0.21 , while revenue for the quarter reached $41.92M .
Earnings released on 30 Jun 2024
EPS came in at -$0.24 , while revenue for the quarter reached $385.88K .
Earnings released on 31 Mar 2024
EPS came in at -$0.24 , while revenue for the quarter reached $389.33K .
Earnings released on 31 Dec 2023
EPS came in at -$0.60 , while revenue for the quarter reached $324.84K .
Earnings released on 30 Sept 2023
EPS came in at -$0.30 , while revenue for the quarter reached $4.14M .
Earnings released on 30 Jun 2023
EPS came in at -$0.52 , while revenue for the quarter reached $97.18K .
Earnings released on 31 Mar 2023
EPS came in at -$0.27 , while revenue for the quarter reached $49.11K .
Earnings released on 31 Dec 2022
EPS came in at -$0.57 , while revenue for the quarter reached $126.80K .
Earnings released on 30 Sept 2022
EPS came in at -$0.30 , while revenue for the quarter reached $2.90M .
Earnings released on 29 Jun 2022
EPS came in at -$0.68 , while revenue for the quarter reached $512.72K .
1541.HK Stock Performance
Access detailed 1541.HK performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.